

**Daria Lemann-Blumenthal**  
CEO  
Company: **Belkin Laser**

BELKIN Laser is developing an automated one-second glaucoma laser treatment, aimed at revolutionizing accessibility to glaucoma care by becoming the first-line choice for glaucoma therapy for every patient, all over the world. | Glaucoma is a chronic, asymptomatic disease, causing progressive optic nerve degeneration. It is the leading cause of irreversible blindness globally. Although the disease is incurable, progression may be delayed by reducing IOP (Intraocular Pressure), thus preventing visual field impairment and blindness. | BELKIN Laser's innovative technology provides a solution not only for Open Angle Glaucoma (70% of total glaucoma cases) but is also an exclusive solution for Angle Closure Glaucoma (ACG) (30%), which is most common among Asian populations.